The WORx email address is provided, along with website addresses for the home page, enrollment, queries, data upload, and statistics. Contact information is provided for the Executive Director and Records Analyst. Statistics for 2017 cover the state population (573,720), DEA registered prescribers (3,112), and DEA registered dispensers (118). Nineteen WORx available reports are listed. Funding for WORx in 2018 came from licensing fees, controlled substance registration fees, and the regulatory board fund. Staff numbers for 2018 are reported for the following job classifications: operational (1), technical (0), analytical (0), and "other" (1). Some key dates in WORx's development are the enabling legislation (March 2003), becoming operational (summer 2004), initial user access (October 2004), on-line access (October 2004), and electronic reporting (summer 2004). Source information is provided for state statutes and rules relevant to WORx's policies and procedures. Reporting frequency for monitored drugs is the next business day. Reporting is not required if no monitored drugs were prescribed. The monitored drugs are controlled substances in schedules II, III, IV, and V. Reporting is also required for the administration or dispensing of naloxone. The WORx has the authority to monitor other substances. Miscellaneous WORx capabilities and policies are listed. Both prescribers and dispensers are required to enroll with WORx, but they are not required to use it. Law enforcement personnel can access a patient's data on drug prescriptions only if the patient is under active investigation. All but de-identified data are purged after 2 years. Training in the use of WORx is neither required nor available. The technological capabilities of WORx are reported, Reports authorized and produced on WORx data are listed by requestor type.
Prescription Drug Monitoring Program: Wyoming State Profile
NCJ Number
253041
Date Published
April 2019
Length
8 pages
Annotation
Information and data are presented for the Wyoming prescription drug monitoring program named WORx, which is administered by the Wyoming Board of Pharmacy.
Abstract